Pulmonary Arterial Hypertension

About

Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Articles

Pharmacologic Strategies for Management of Pulmonary Arterial Hypertension

Citation:

US Cardiology Review 2016;10(2):78–84

Vascular Access and Chronic Total Occlusion Angioplasty

Citation:

Interventional Cardiology Review 2015;10(2):90–3

Pulmonary Hypertension

Citation:

European Cardiology Review 2015;10(1):9–11

A Practical Clinical Approach to the Diagnosis and Treatment of Patients with Pulmonary Hypertension

Citation:

European Cardiology Review 2015;10(2):102–7